<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30720" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Typhoid Vaccine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Van Camp</surname>
            <given-names>Roscoe O.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Shorman</surname>
            <given-names>Mahmoud</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Roscoe Van Camp declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mahmoud Shorman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>7</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30720.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">This educational activity&#x000a0;discusses&#x000a0;vaccinations against typhoid, detailing their indications, mechanisms, administration methods, adverse effects, contraindications, and the rationale for use in both endemic and nonendemic areas. This activity aids healthcare providers in effectively recommending and administering typhoid vaccines when appropriate.&#x000a0;In the United States and other high-income countries, these vaccines&#x000a0;are typically given to travelers, laboratory workers, and individuals in close contact with patients with Salmonella serotype Typhi infections. Poor water, sanitation, and hygiene infrastructure in endemic regions contribute to high infection rates. The World Health Organization (WHO) recommends routine vaccination&#x000a0;for&#x000a0;children aged 6 months to 15 years in these areas, particularly those facing&#x000a0;outbreaks of drug-resistant&#x000a0;strains of&#x000a0;<italic toggle="yes">S</italic> Typhi.</p>
        <p>The United States Food and Drug Administration (FDA) has approved&#x000a0;2&#x000a0;unconjugated typhoid vaccines: an oral attenuated live virus and an injectable polysaccharide. The WHO prequalifies&#x000a0;3&#x000a0;commercially available typhoid conjugate vaccines for use in endemic areas. An interprofessional team approach involving physicians, nurses, public health professionals, and pharmacists is crucial for successfully implementing typhoid vaccination programs. This approach&#x000a0;involves identifying at-risk populations, providing timely vaccination, and educating&#x000a0;patients regarding&#x000a0;the importance of immunization and maintaining food and water protections to enhance vaccine uptake, reduce the incidence of typhoid fever, and slow the&#x000a0;development of antimicrobial resistance.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Apply knowledge of the medical rationale, indications, contraindications, and&#x000a0;local licensing regarding&#x000a0;typhoid vaccination to appropriately administer typhoid vaccine to appropriate individuals and populations at risk of typhoid infection.</p></list-item><list-item><p>Assess the efficacy and safety profiles of the different typhoid vaccines.</p></list-item><list-item><p>Identify the current guidelines and best practices&#x000a0;regarding&#x000a0;typhoid vaccination and other preventive measures in the United States and other regions.</p></list-item><list-item><p>Implement collaboration&#x000a0;between interprofessional healthcare team members&#x000a0;to optimize&#x000a0;vaccine delivery&#x000a0;for&#x000a0;improved&#x000a0;patient outcomes by applying a thorough understanding of typhoid vaccination in different patient populations.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30720&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30720">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30720.s2" sec-type="Indications">
        <title>Indications</title>
        <p>While typhoid fever is uncommon in the United States, its causative agent,&#x000a0;<italic toggle="yes">Salmonella enterica</italic> serotype Typhi (<italic toggle="yes">S&#x000a0;</italic>Typhi), is one of the world's&#x000a0;leading&#x000a0;infectious public health threats. The bacteria is endemic&#x000a0;to Africa, Latin America, and Asia, particularly in the southern region of this continent.&#x000a0;<italic toggle="yes">S</italic> Typhi&#x000a0;causes 11 to 20 million infections and 128,000 to 161,000 deaths annually, primarily in children.<xref ref-type="bibr" rid="article-30720.r1">[1]</xref> This bacterium is endemic to many low and middle-income countries with poor water, sanitation, and hygiene&#x000a0;infrastructure. Forty-four countries, primarily in Africa and Asia, have infection rates exceeding 100 per 100,000 person-years.<xref ref-type="bibr" rid="article-30720.r2">[2]</xref> High rates of enteric fever&#x000a0;exact significant&#x000a0;personal, community, healthcare, and economic costs in endemic countries.</p>
        <p>Most&#x000a0;<italic toggle="yes">S</italic> Typhi or <italic toggle="yes">S</italic> Paratyphi infections in the United States and other&#x000a0;high-income countries (HICs)&#x000a0;occur&#x000a0;during&#x000a0;travel to&#x000a0;countries where the infection is endemic or contact with persons infected with <italic toggle="yes">S</italic> Typhi. Approximately 400 people&#x000a0;in the United States develop typhoid fever every year. International travel, mainly to India or Pakistan, accounts for 85% of cases, with visiting friends and family as the primary reason for travel.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/typhoid-fever/php/surveillance/annual-summary-2020.html">[24]</ext-link> Less than&#x000a0;6% of&#x000a0;patients&#x000a0;with Salmonella Typhi infections received a typhoid vaccine in the previous 5 years. Localized transmission or outbreaks occur annually in the United States and primarily&#x000a0;originate from ill or convalescent household members or a food handler who is an asymptomatic carrier.</p>
        <p>
<bold>Vaccination in the United States and Other Nonendemic Countries</bold>
</p>
        <p>The United States Advisory Committee for Immunization Practice (ACIP) and the Center for Disease Control's 2024 Yellow Book indicate vaccination for the following individuals:</p>
        <list list-type="bullet">
          <list-item>
            <p>Individuals&#x000a0;traveling to endemic areas, particularly to South Asia, and those with health or travel-related risks traveling to other endemic countries. These individuals include children, travelers who are&#x000a0;visiting friends and relatives (even for short stays), people who have spent (or are currently spending) months or longer traveling, patients with anatomical or functional asplenia,&#x000a0;receiving acid suppressant therapy, or people who wish to be vaccinated.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/typhoid-and-paratyphoid-fever#agent">[25]</ext-link></p>
          </list-item>
          <list-item>
            <p>Individuals&#x000a0;with intimate exposure (eg, household contact) to a person&#x000a0;documented to be a chronic carrier of&#x000a0;Salmonella Typhi.<xref ref-type="bibr" rid="article-30720.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Individuals&#x000a0;working in a laboratory setting with&#x000a0;specimens that may be typhoid-contaminated.<xref ref-type="bibr" rid="article-30720.r3">[3]</xref></p>
          </list-item>
        </list>
        <p>The United States Food and Drug Administration (FDA) has approved 2 unconjugated vaccines to prevent Salmonella Typhi infection in the United States: an oral attenuated live virus vaccine (Ty21a) and an injectable Vi-capsular polysaccharide vaccine (ViPS or ViCPS).</p>
        <list list-type="bullet">
          <list-item>
            <p>The oral Ty21a vaccine (Vivotif, Emergent Biosolutions) was first licensed in Europe in 1983 and the United States in 1989 and is FDA-approved for adults and children&#x000a0;older than 6. This vaccine series consists of 4 capsules, each taken every 2&#x000a0;days. ACIP recommends&#x000a0;updating&#x000a0;the Ty21a vaccine every&#x000a0;5 years with the entire 4-dose series&#x000a0;for patients with&#x000a0;continuous or recurrent possible exposure to&#x000a0;<italic toggle="yes">S</italic>&#x000a0;Typhi.<xref ref-type="bibr" rid="article-30720.r3">[3]</xref> Other countries recommend a 3-capsule series and repeated vaccination every 1 to 7 years.<xref ref-type="bibr" rid="article-30720.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>The ViPS vaccine is available in several dosage forms and was first licensed in the United States in 1994. The FDA&#x000a0;has approved the ViPS vaccine for adults and children aged 2 and older.&#x000a0;ACIP recommends administering booster vaccines every 2 years if the risk for&#x000a0;<italic toggle="yes">S</italic> Typhi continues or recurs.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/typhoid-and-paratyphoid-fever#agent">[25]</ext-link>&#x000a0;The WHO recommends booster vaccines every 3 years.<xref ref-type="bibr" rid="article-30720.r4">[4]</xref></p>
          </list-item>
        </list>
        <p>ACIP does not recommend the typhoid vaccine for routine immunization in the United States.<xref ref-type="bibr" rid="article-30720.r5">[5]</xref>&#x000a0;Many&#x000a0;nonendemic countries have recommendations similar to those of the United States (eg, Canada and Europe). Clinicians&#x000a0;should follow country-specific recommendations.<xref ref-type="bibr" rid="article-30720.r4">[4]</xref>&#x000a0;As Salmonella Typhi infection&#x000a0;confers incomplete immunity, patients with a history of typhoid infection require vaccination&#x000a0;according to&#x000a0;the same criteria as those with no prior infection.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/typhoid-and-paratyphoid-fever#agent">[25]</ext-link></p>
        <p>
<bold>Vaccination in Endemic Countries</bold>
</p>
        <p>The World Health Organization (WHO) recommends typhoid vaccines as part of routine immunization programs to prevent and control typhoid fever in endemic countries. Implementation priority is given to countries with a high burden of typhoid disease or multidrug-resistant <italic toggle="yes">S</italic> Typhi.<xref ref-type="bibr" rid="article-30720.r4">[4]</xref>&#x000a0;The typhoid vaccine&#x000a0;is&#x000a0;ideally&#x000a0;administered during infancy. Catch-up vaccination&#x000a0;may be administered&#x000a0;to patients&#x000a0;aged 15 and younger&#x000a0;if available, and the decision is supported by epidemiological evidence. Typhoid conjugate vaccines (TCVs) are preferred in endemic countries.<xref ref-type="bibr" rid="article-30720.r4">[4]</xref> As of February 2024, the WHO has prequalified 3 TCVs; other TCVs are&#x000a0;undergoing&#x000a0;the WHO prequalification process or are licensed in individual countries.&#x000a0;TCV vaccines are not licensed in the United States or other nonendemic countries.</p>
        <list list-type="bullet">
          <list-item>
            <p>Typbar-TCV<sup>&#x000ae;&#x000a0;</sup>(Bharat BioNtech International Ltd, India; prequalified December 2017) can be administered to children 6 months and older and adults aged 45 and younger.&#x000a0;The WHO recommends an initial dose at 9 months, coadministered with other routine vaccines or before age 2.<xref ref-type="bibr" rid="article-30720.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>TyphiBev<sup>TM</sup>&#x000a0;(Biological E Ltd, India; prequalified December 2020) may be administered to patients 6 months to 45 years.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266125/">[26]</ext-link></p>
          </list-item>
          <list-item>
            <p>SKYTyphoid<sup>TM</sup>&#x000a0;(SK Bioscience Co. Ltd, South Korea; prequalified February 2024) is safe and effective&#x000a0;for patients 6 months to 45 years.<xref ref-type="bibr" rid="article-30720.r6">[6]</xref></p>
          </list-item>
        </list>
        <p>As with vaccination in nonendemic countries,&#x000a0;patients with a history of typhoid infection require primary immunization&#x000a0;according to&#x000a0;the same criteria as those with no prior infection. The optimal&#x000a0;TCV booster schedule across age groups is undetermined.</p>
      </sec>
      <sec id="article-30720.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>
<bold>Unconjugated Typhoid Vaccines</bold>
</p>
        <p><bold>Ty21a vaccine:</bold>&#x000a0;The live attenuated Ty21a strain lacks uridine-diphosphate-galactose-4-epimerase, resulting in the inability to manufacture Vi polysaccharide and a cytoplasmic accumulation of galactose that eventually causes cell lysis.<xref ref-type="bibr" rid="article-30720.r7">[7]</xref> This vaccine induces the production of serum and intestinal mucosal antibodies&#x000a0;against O, H, and other surface antigens but not against the Vi polysaccharide. The&#x000a0;strength of the initial response mediated by IgA antibody-secreting cells and the presence of&#x000a0;anti-O immunoglobulin G antibodies are the best markers of protection.<xref ref-type="bibr" rid="article-30720.r4">[4]</xref>&#x000a0;A long-lasting cell-mediated immunity develops and includes a specific cytotoxic T-lymphocyte response.</p>
        <p>The Ty21a vaccine&#x000a0;has a cumulative efficacy of 43% (CI 30%-53%; 4 trials) over 1 to 5 years of follow-up among participants aged 3 to 44.<xref ref-type="bibr" rid="article-30720.r1">[1]</xref> The patient's age&#x000a0;during vaccination does not affect this efficacy.&#x000a0;Other oral vaccines, such as Rotarix, polio, and cholera,&#x000a0;demonstrate&#x000a0;poor efficacy in low and middle-income countries (LMIC) due to various factors, including higher rates of concomitant gastrointestinal disease, microbial dysbiosis, and mucosal tolerance.<xref ref-type="bibr" rid="article-30720.r1">[1]</xref> The Ty21a vaccine may be more effective for the populations&#x000a0;of high-income countries, but no evidence exists to support this. Maximum effectiveness requires taking all doses.</p>
        <p><bold>ViPS&#x000a0;vaccine:</bold>&#x000a0;Immunization initially induces increased production of IgG anti-Vi antibodies, which are found in elevated levels in the serum. The immune system develops an immunologic memory in response to ViPS vaccination, as&#x000a0;polysaccharide antigens do not induce T-cell production. Antibody titer levels decline&#x000a0;significantly by the third year after immunization.<xref ref-type="bibr" rid="article-30720.r4">[4]</xref>&#x000a0;This vaccine has an estimated cumulative efficacy of 57% (CI 44%-69%; 5 trials)&#x000a0;over&#x000a0;1 to 3 years among participants aged 2 to 50.<xref ref-type="bibr" rid="article-30720.r1">[1]</xref>&#x000a0;The patient's age is&#x000a0;unlikely to&#x000a0;affect vaccine efficacy, although insufficient power and a large margin of uncertainty of vaccine efficacy in children younger than 5 may&#x000a0;obscure any significant differences.<xref ref-type="bibr" rid="article-30720.r4">[4]</xref></p>
        <p>
<bold>Typhoid Conjugate Vaccines</bold>
</p>
        <p>All TCVs contain&#x000a0;25 &#x003bc;g of Vi polysaccharide conjugated with a protein carrier.&#x000a0;This carrier component&#x000a0;engages&#x000a0;B and T-cells,&#x000a0;inducing&#x000a0;germinal center development in the spleen and lymph nodes. Within germinal centers, polysaccharide-specific B-cells proliferate and differentiate&#x000a0;through hypermutation of the antibody genes. Follicular helper T-cells&#x000a0;aid this process once activated by the protein carrier&#x000a0;presented&#x000a0;by the major histocompatibility complex on the B-cell surface.<xref ref-type="bibr" rid="article-30720.r8">[8]</xref>&#x000a0;An increased affinity of the B-cell receptor antibody to the&#x000a0;antigen&#x000a0;increases the aid provided by T-cells via cytokines and direct cell-to-cell interaction.&#x000a0;Repeated cycles&#x000a0;produce higher-affinity antibodies and antibody class switching,&#x000a0;similar to the immune response during a typical infection. B-cells in germinal&#x000a0;centers that do not engage T-cells undergo apoptosis.<xref ref-type="bibr" rid="article-30720.r8">[8]</xref></p>
        <p>Along with a 2024 systematic review and meta-analysis, new randomized controlled trials (RCTs) studying&#x000a0;the efficacy of&#x000a0;typhoid vaccines for preventing culture-confirmed <italic toggle="yes">S</italic> Typhi infection support the results reported in previous reviews, such as the 2018 Cochrane Review.&#x000a0;These study data include newer conjugate vaccines and extended observation periods.<xref ref-type="bibr" rid="article-30720.r1">[1]</xref><xref ref-type="bibr" rid="article-30720.r9">[9]</xref><xref ref-type="bibr" rid="article-30720.r10">[10]</xref> The systematic review found no&#x000a0;RCTs studying&#x000a0;typhoid vaccine efficacy&#x000a0;in&#x000a0;populations&#x000a0;of nonendemic countries; all&#x000a0;data are from&#x000a0;studies in&#x000a0;endemic countries.<xref ref-type="bibr" rid="article-30720.r1">[1]</xref>&#x000a0;RCTs studying the&#x000a0;efficacy of conjugated vaccines are few but growing in number. An update to the 2018 Cochrane Review of Typhoid Vaccines is pending; a protocol was registered with the Cochrane Library in March 2023.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266125/">[26]</ext-link> This update will&#x000a0;focus&#x000a0;solely on TCVs. Human challenge and other immunogenicity studies provide additional&#x000a0;evidence of vaccine efficacy, cited here for vaccines without efficacy data.</p>
        <p><bold>ViTT vaccines:</bold>&#x000a0;The Vi-tetanus toxoid conjugate (Vi-TT) vaccine is&#x000a0;conjugated with a nontoxic tetanus toxoid carrier.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266125/">[26]</ext-link>&#x000a0;Vi-TT&#x000a0;is available in&#x000a0;2 formulations: Typbar-TCV<sup>&#x000ae;</sup>&#x000a0;and PedaTyph<sup>TM</sup>&#x000a0;(BioMed, India).<bold>&#x000a0;</bold>A single dose of the&#x000a0;Typbar-TCV<sup>&#x000ae;</sup>&#x000a0;Vi-TT vaccine has a cumulative efficacy of 83% (CI 77% to 88%; 4 trials) 1 to 2 years post-immunization&#x000a0;in infants and children aged 6 months to 16 years.<xref ref-type="bibr" rid="article-30720.r1">[1]</xref> The most recent Typbar-TCV<sup>&#x000ae;&#x000a0;</sup>Vi-TT vaccine trial analysis in Malawian children aged 9 months to 12 years&#x000a0;showed an efficacy of 78.3% (CI 66.3% to 86.1%) 4 years after a single dose.<xref ref-type="bibr" rid="article-30720.r9">[9]</xref> Differences in efficacy were nonsignificant across age groups.</p>
        <p>In an outbreak setting, the&#x000a0;Typbar-TCV<sup>&#x000ae;</sup>&#x000a0;Vi-TT vaccine&#x000a0;demonstrated 95% effectiveness (93% to 96%) against&#x000a0;culture-confirmed <italic toggle="yes">S</italic> Typhi&#x000a0;in children aged 6 months to 10 years&#x000a0;during a study conducted from&#x000a0;February 21, 2018, to December 31, 2019, in Hyderabad, Pakistan.<xref ref-type="bibr" rid="article-30720.r11">[11]</xref> Despite only moderate deployment, this vaccine curtailed the outbreak. An alternate formulation of Vi-TT (PedaTyph<sup>TM</sup>) is licensed and marketed only in India.<xref ref-type="bibr" rid="article-30720.r4">[4]</xref>&#x000a0;This vaccine can be&#x000a0;administered to children 3 months or older.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266125/">[26]</ext-link>&#x000a0;The 2018 Cochrane review reported an efficacy of 94% (CI 0%-101%) based on a single study. The actual effect is uncertain due to a wide confidence interval and a lack of unclustering&#x000a0;during&#x000a0;statistical analysis of the study data.<xref ref-type="bibr" rid="article-30720.r12">[12]</xref></p>
        <p>
<bold>Vi-CMR<sub>197</sub>&#x000a0;vaccine</bold>
</p>
        <p>TyphiBev<sup>TM</sup>&#x000a0;is a Vi-CMR<sub>197 </sub>conjugate vaccine comprising&#x000a0;a Vi protein attached to a&#x000a0;mutant nontoxic&#x000a0;diphtheria toxoid. Vi-CMR<sub>197</sub>&#x000a0;is non-inferior to the Vi-TT vaccine and demonstrates&#x000a0;a seroconversion rate of 99.0% (CI 97.1% to 97.6%) versus 99.3% (CI 97.6% to 99.9%) for Vi-TT based on a seroconversion threshold of 2 &#x003bc;g/mL.<xref ref-type="bibr" rid="article-30720.r13">[13]</xref>&#x000a0;Immunogenicity response rates were consistent across age ranges from 6 months to 54 years. The serum geometric mean titers (GMTs) of anti-Vi IgG antibodies induced by Vi-CMR<sub>197</sub>&#x000a0;and&#x000a0;Vi-TT were comparable overall and across age ranges.<xref ref-type="bibr" rid="article-30720.r13">[13]</xref></p>
        <p>
<bold>Vi-Diphtheria toxoid vaccine</bold>
</p>
        <p>SKYTyphoid<sup>&#x000ae;</sup>&#x000a0;is a Vi-diphtheria toxoid vaccine (Vi-DT).&#x000a0;The&#x000a0;Vi-DT seroconversion rate&#x000a0;of&#x000a0;99.7% (97.5%, CI 98.0% to 100.0%) is non-inferior to Vi-TT vaccination (99.1%, CI 94.3% to 100.0%)&#x000a0;in participants aged 6 months to 45 years during a phase 3 trial based on a seroconversion threshold of 0.14 &#x003bc;g/mL.<xref ref-type="bibr" rid="article-30720.r6">[6]</xref> No differences&#x000a0;were observed across age strata. The anti-Vi IgG GMTs showed no differences&#x000a0;across age strata compared to Vi-TT. However, significant differences occurred&#x000a0;in participants aged 6 to 24 months; this group had more adverse effects and a significantly lower mean GMT compared to Vi-TT (50.2 vs 73.4 IU/mL) at 24 months.<xref ref-type="bibr" rid="article-30720.r6">[6]</xref>&#x000a0;Further study is needed to&#x000a0;elaborate&#x000a0;on this finding.</p>
        <p>
<bold>Vi-rEPA vaccine</bold>
</p>
        <p>Vi-rEPA is&#x000a0;an early TCV conjugated with a recombinant exoprotein A from <italic toggle="yes">Pseudomonas aeruginosa</italic>. The efficacy of Vi-rEPA<bold>&#x000a0;</bold>is 89% (CI 77%-95%; 1 trial) for 4 years&#x000a0;post-administration of 2 vaccine doses.<xref ref-type="bibr" rid="article-30720.r1">[1]</xref>&#x000a0;Relevant studies did not include children&#x000a0;younger than 2.<xref ref-type="bibr" rid="article-30720.r12">[12]</xref> This vaccine&#x000a0;is not&#x000a0;commercially available.</p>
      </sec>
      <sec id="article-30720.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Unconjugated Vaccines</bold>
</p>
        <p><bold>Ty21a:&#x000a0;</bold>Vaccination requires 4 oral enteric-coated capsules, each taken 48 hours apart. Each capsule&#x000a0;is&#x000a0;taken&#x000a0;1 hour before&#x000a0;or at least 2 hours after a meal with water cooler than body temperature&#x000a0;(&#x02264;37.0 &#x000b0;C).&#x000a0;The&#x000a0;capsules&#x000a0;must be&#x000a0;refrigerated&#x000a0;until use. The patient must complete&#x000a0;this&#x000a0;series at least&#x000a0;1 week before a potential exposure.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/typhoid-and-paratyphoid-fever#prevent">[25]</ext-link></p>
        <p><bold>ViPS:</bold> Vaccination requires a single 0.5 mL (25 &#x003bc;g) intramuscular dose at least 2 weeks before a potential exposure.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/typhoid-and-paratyphoid-fever#prevent">[25]</ext-link></p>
        <p>
<bold>Typhoid Conjugate Vaccines </bold>
</p>
        <p>All TCVs require a&#x000a0;single intramuscular dose, except for the PedaTyph<sup>TM</sup>&#x000a0;and Vi-rEPA vaccines, which require a 2-dose primary series separated over 4 to 8 weeks.<xref ref-type="bibr" rid="article-30720.r4">[4]</xref>&#x000a0;The optimal booster schedules&#x000a0;for most TCVs remain undefined and depend on factors such as the vaccination age and the degree of natural boosting in the individual patient.<xref ref-type="bibr" rid="article-30720.r4">[4]</xref><xref ref-type="bibr" rid="article-30720.r14">[14]</xref>&#x000a0;The manufacturer recommends an initial PedaTyph<sup>TM</sup>&#x000a0;immunization for&#x000a0;infants aged 3 to 23 months, a booster at 24 to 30 months, and boosters every 10 years&#x000a0;afterward.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266125/">[26]</ext-link></p>
        <p>
<bold>Coadministration With Other Vaccines</bold>
</p>
        <p>The Ty21a and ViPS vaccines can be administered with other travel or childhood vaccines, including live ones. Likewise, TCVs can be administered safely with other childhood vaccines, as demonstrated by the Malawi and Burkina Faso studies. Specifically, measles-rubella vaccines are safe and effective when administered at 9 and 15 months, yellow fever vaccine at 9 months, and meningococcal vaccine at 15 months.<xref ref-type="bibr" rid="article-30720.r14">[14]</xref> Several recent and ongoing TCV study protocols require the&#x000a0;concurrent administration of the study vaccine&#x000a0;and routine childhood vaccines.<xref ref-type="bibr" rid="article-30720.r12">[12]</xref></p>
      </sec>
      <sec id="article-30720.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Typhoid vaccines currently in use are safe and generally well tolerated. They may cause&#x000a0;mild local or systemic adverse effects. However, study data shows these effects are&#x000a0;similar to those caused by placebo or comparator vaccines used in trials (meningococcal, hepatitis, pneumococcal, or other TCV). Multiple&#x000a0;studies report no serious adverse events associated with TCVs to date.<xref ref-type="bibr" rid="article-30720.r1">[1]</xref><xref ref-type="bibr" rid="article-30720.r6">[6]</xref><xref ref-type="bibr" rid="article-30720.r1">[1]</xref><xref ref-type="bibr" rid="article-30720.r12">[12]</xref><xref ref-type="bibr" rid="article-30720.r10">[10]</xref><xref ref-type="bibr" rid="article-30720.r12">[12]</xref><xref ref-type="bibr" rid="article-30720.r13">[13]</xref><xref ref-type="bibr" rid="article-30720.r15">[15]</xref></p>
        <p>Each vaccine is associated with specific adverse events:</p>
        <list list-type="bullet">
          <list-item>
            <p>The oral Ty21a vaccine is commonly associated with&#x000a0;fever&#x000a0;compared to placebo.<xref ref-type="bibr" rid="article-30720.r12">[12]</xref> Vomiting, diarrhea, nausea, and abdominal pain occur with similar frequency as with placebo.</p>
          </list-item>
          <list-item>
            <p>ViPS is commonly associated with injection site swelling and pain compared to placebo.<xref ref-type="bibr" rid="article-30720.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p>Vi-rEPA&#x000a0;is associated with increased rates of&#x000a0;fever after each vaccine dose.&#x000a0;Swelling at the injection site&#x000a0;was more common&#x000a0;after the second dose compared to placebo.<xref ref-type="bibr" rid="article-30720.r12">[12]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30720.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Pregnant and Lactating Women</bold>
</p>
        <p>Safety data for typhoid vaccine administration to pregnant and lactating women is lacking for all vaccines. The ViPS vaccine and TCVs are thought to have minimal or absent risk.<xref ref-type="bibr" rid="article-30720.r4">[4]</xref>&#x000a0;These&#x000a0;can be safely administered if indicated.<xref ref-type="bibr" rid="article-30720.r4">[4]</xref>&#x000a0;<xref ref-type="bibr" rid="article-30720.r16">[16]</xref>Live vaccines are not recommended during pregnancy due to theoretical risks to the pregnant&#x000a0;woman or fetus.<xref ref-type="bibr" rid="article-30720.r4">[4]</xref> The CDC recommends against&#x000a0;administering Ty21a&#x000a0;to pregnant women and avoiding conception until 4 weeks after immunization.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/typhoid-and-paratyphoid-fever#prevent">[25]</ext-link></p>
        <p>
<bold>Concurrent Conditions or Medications</bold>
</p>
        <p>The CDC recommends the ViPS vaccine&#x000a0;for patients who are immunocompromised.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/typhoid-and-paratyphoid-fever#prevent">[25]</ext-link>&#x000a0;The ViPS vaccine and TCVs&#x000a0;may be safely administered to&#x000a0;patients who are immunocompromised, including those with HIV. However, an immunocompromised patient may demonstrate reduced production of protective antibodies&#x000a0;following non-live typhoid vaccinations. This phenomenon is pronounced in&#x000a0;patients who&#x000a0;are severely immunocompromised due to conditions (eg, symptomatic human immunodeficiency virus/acquired immunodeficiency syndrome, chronic lymphocytic leukemia, hematopoietic stem cell transplant, generalized cancer) or&#x000a0;receiving immunosuppressive medications (eg, alkylating agents, antimetabolites, biologic agents.&#x000a0;In patients with HIV, antibody induction with ViPS and TCVs correlates directly&#x000a0;to the CD4<sup>+</sup> count.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/typhoid-and-paratyphoid-fever#prevent">[25]</ext-link></p>
        <p>The CDC also recommends against&#x000a0;administering&#x000a0;the live Ty21a vaccine&#x000a0;to&#x000a0;individuals with a known suppression of cell-mediated immunity, who have been&#x000a0;receiving high-dose steroid therapy for 2 weeks or longer, or who are receiving chemotherapeutic or radiation therapy.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/typhoid-and-paratyphoid-fever#prevent">[25]</ext-link> The WHO considers Ty21a safe to&#x000a0;administer&#x000a0;to&#x000a0;patients with HIV&#x000a0;and a CD4<sup>+</sup> count&#x000a0;of 200 cells/mm<sup>3</sup>&#x000a0;or greater (CD4<sup>+</sup> &#x0003e;25% in children younger than 5).<xref ref-type="bibr" rid="article-30720.r4">[4]</xref>&#x000a0;The immunogenicity&#x000a0;of TY21a may be reduced in&#x000a0;patients&#x000a0;with acute severe gastrointestinal conditions;&#x000a0;immunization for these patients&#x000a0;should be delayed until after recovery. Other minor illnesses are not contraindications&#x000a0;for these vaccines, although some individuals choose to delay vaccination until after recovery.&#x000a0;Antibiotics may reduce immunogenicity, and concurrent&#x000a0;administration with the Ty21a vaccine should be avoided. Various monoclonal antibodies may also interfere with antibody production. An allergic reaction to any vaccine (or any of its components) is a contraindication for that vaccine.</p>
      </sec>
      <sec id="article-30720.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>No monitoring or routine testing is necessary with&#x000a0;any of&#x000a0;the vaccines described.</p>
      </sec>
      <sec id="article-30720.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>There is no toxicity associated with any typhoid vaccination formulation in the literature.</p>
      </sec>
      <sec id="article-30720.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Understanding the rationale for using various typhoid vaccines is critical to providing optimal care to people at risk of typhoid infection in endemic and nonendemic countries. Knowledge of the&#x000a0;presentation of enteric fever, diagnostic and treatment challenges, the rise of antimicrobial resistance, and&#x000a0;implementation considerations&#x000a0;aid healthcare providers in making healthcare&#x000a0;recommendations regarding vaccination. This knowledge is also necessary to&#x000a0;improve the implementation of vaccination programs&#x000a0;and widespread prevent enteric illness.</p>
        <p>
<bold>Presentation and Diagnosis</bold>
</p>
        <p>Clinicians must&#x000a0;advise&#x000a0;healthy patients&#x000a0;living in or traveling to endemic countries of the risk of&#x000a0;<italic toggle="yes">S</italic> Typhi infection, its associated risk factors, early signs and symptoms, and when and how to&#x000a0;seek help should they become ill. Practitioners must also&#x000a0;monitor for early signs and symptoms of the disease in patients with typhoid fever to avoid complications and possible death.</p>
        <p><italic toggle="yes">Salmonella enterica</italic> serotype Typhi is a&#x000a0;pathogen found only in humans.&#x000a0;<italic toggle="yes">S</italic> Typhi is ingested through contaminated food or water, particularly in areas with inadequate WASH infrastructure. The bacteria can&#x000a0;withstand&#x000a0;stomach acid and&#x000a0;penetrate the small bowel's epithelial enterocytes or lymphoid tissue.&#x000a0;<italic toggle="yes">S</italic> Typhi is primarily spread by intracellular lymphatic and hematogenous routes.&#x000a0;During typhoid challenge studies,&#x000a0;patients develop a complex immune response to multiple bacterial&#x000a0;antigens; those who become clinically ill do not develop antibodies to the Vi capsular polysaccharide of <italic toggle="yes">S</italic> Typhi.<xref ref-type="bibr" rid="article-30720.r17">[17]</xref>&#x000a0;The closely related&#x000a0;<italic toggle="yes">Salmonella enterica</italic>&#x000a0;serotypes Paratyphi A, B, and C (<italic toggle="yes">S</italic>&#x000a0;Paratyphi) cause an illness&#x000a0;clinically indistinguishable from Salmonella Typhi infection.<xref ref-type="bibr" rid="article-30720.r3">[3]</xref></p>
        <p>Typhoid and paratyphoid fever are collectively&#x000a0;referred to as enteric fever. In endemic areas, enteric fever is frequently confused with other nonspecific febrile illnesses. Following an incubation period of&#x000a0;6 to 30 days, enteric&#x000a0;fever initially presents as&#x000a0;an undifferentiated, progressive fever that increases&#x000a0;with&#x000a0;bacteremia.&#x000a0;Fatigue, anorexia, headache, malaise, and abdominal symptoms&#x000a0;are commonly accompanying symptoms. A&#x000a0;faint macular rash on the trunk and abdomen ("rose spots") and hepatosplenomegaly may also occur.</p>
        <p>Enteric fever&#x000a0;can have severe outcomes, including death. Complications&#x000a0;usually arise&#x000a0;during the&#x000a0;third week of illness; ileocecal perforation, peritonitis,&#x000a0;or septic shock&#x000a0;occur in&#x000a0;30% of patients who&#x000a0;do not receive&#x000a0;treatment.<xref ref-type="bibr" rid="article-30720.r18">[18]</xref> Patients&#x000a0;may have a&#x000a0;protracted recovery&#x000a0;lasting weeks or months. The bacteria may be present in the stool for months after infection. Five percent of&#x000a0;patients&#x000a0;become&#x000a0;carriers and excrete&#x000a0;<italic toggle="yes">S</italic>&#x000a0;Typhi in the stool for over a year. Relapse of fever occurs in about 10% of untreated patients. Death occurs in 10% to 30% of patients who remain untreated.<xref ref-type="bibr" rid="article-30720.r18">[18]</xref></p>
        <p>Culture from blood, stool, urine, bone marrow, duodenal contents, or skin rash is the gold standard for typhoid fever confirmation. However, blood culture (the most common laboratory testing) has low sensitivity (50% to 66%) for patients in endemic areas and is frequently unavailable in&#x000a0;these regions. The sensitivity of blood culture testing is significantly greater (&#x0003e;90%)&#x000a0;for travelers.<xref ref-type="bibr" rid="article-30720.r19">[19]</xref> Newer rapid diagnostic tests are becoming increasingly available.</p>
        <p>
<bold>Treatment and Antimicrobial Resistance</bold>
</p>
        <p>The rapid development of&#x000a0;<italic toggle="yes">S</italic> Typhi drug resistance worldwide makes antibiotic therapy challenging.<xref ref-type="bibr" rid="article-30720.r20">[20]</xref>&#x000a0;The WHO recommends initial treatment pending culture for patients with suspected enteric fever. Treatment varies between areas with and without known resistance to ciprofloxacin medications. Treatment is a third-generation cephalosporin for&#x000a0;severe illness in all areas and a fluoroquinolone antibiotic or azithromycin for milder illness, depending on where the infection was acquired.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2022.02">[27]</ext-link>&#x000a0;Knowing the sensitivity pattern for the area where the infection&#x000a0;occurred guides initial antibiotic therapy.<xref ref-type="bibr" rid="article-30720.r21">[21]</xref><xref ref-type="bibr" rid="article-30720.r22">[22]</xref>&#x000a0;A lack of access to affordable healthcare in many endemic countries, difficulties in diagnosis&#x000a0;due to undifferentiated illness, poor diagnostic tools, and potentially severe outcomes&#x000a0;contribute to the need for empiric therapy.<xref ref-type="bibr" rid="article-30720.r14">[14]</xref></p>
        <p>The high rates of infection in many endemic countries and the use of empiric treatment place evolutionary pressure on the development of antimicrobial resistance, posing a significant global health threat.&#x000a0;<italic toggle="yes">S</italic> Typhi acquires resistance genes from or transmits genes to other <italic toggle="yes">Salmonella</italic> species&#x000a0;and other microbes. Multidrug-resistant (XDR) strains&#x000a0;demonstrate resistance to&#x000a0;ampicillin, trimethoprim-sulfamethoxazole, and chloramphenicol. The emergence of XDR typhoid in Pakistan in 2016 and its spread to at least 16 other countries is an alarming public health issue.<xref ref-type="bibr" rid="article-30720.r18">[18]</xref> XDR strains&#x000a0;also resist third-generation cephalosporins, leaving azithromycin and meropenem as the only effective antibiotics.<xref ref-type="bibr" rid="article-30720.r14">[14]</xref><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2022.02">[27]</ext-link><xref ref-type="bibr" rid="article-30720.r14">[14]</xref></p>
        <p>
<bold>Implementation</bold>
</p>
        <p>Highly effective vaccines are vital in preventing typhoid disease and the development of antimicrobial resistance globally.&#x000a0;The first whole-cell typhoid vaccines emerged&#x000a0;during the late 19th century but were associated with a high rate of&#x000a0;severe side effects. Safe and effective unconjugated vaccines replaced these&#x000a0;in the 1990s. However, unconjugated vaccines&#x000a0;confer&#x000a0;insufficient&#x000a0;immunity to effectively prevent illness and outbreaks in endemic countries. The need for multiple doses and a limited age range for administering the Ty21a vaccine further limits the usefulness of this vaccine type in the most affected populations.</p>
        <p>TCVs are changing the landscape of typhoid prevention and are now one&#x000a0;of many routine childhood vaccines in highly endemic countries. They are also used to quell typhoid outbreaks. For example,&#x000a0;TCV was effective in limiting an XDR outbreak in Pakistan in 2018 and 2019 that&#x000a0;affected 14,984 people.&#x000a0;Due to their importance in preventing XDR typhoid,&#x000a0;TCVs are on the WHO list of essential medicines for priority diseases.<xref ref-type="bibr" rid="article-30720.r1">[1]</xref></p>
        <p>
<bold>Nonendemic countries</bold>
</p>
        <p>In non endemic countries, including the United States, healthcare workers who provide primary care and vaccines to, or are in contact with, travelers must be aware of the increased risk of enteric and other illnesses. These travelers should also be informed of the increased risk of enteric infection if they visit certain regions. Nurse practitioners, primary care physicians,&#x000a0;and pharmacists should direct patients to local health units or other practitioners who provide travel advice. Healthcare practitioners&#x000a0;administering&#x000a0;the vaccine should understand the indications, contraindications, and proper administration.</p>
        <p>Travelers from nonendemic countries must understand that the typhoid vaccine prevents approximately&#x000a0;50% to 66% of typhoid fever infections.&#x000a0;Immunization against <italic toggle="yes">S</italic> Typhi&#x000a0;does not prevent paratyphoid fever or other gastrointestinal illnesses&#x000a0;and does not&#x000a0;preclude the need for food and water safety precautions, amongst other health measures.&#x000a0;Frequent hand-washing and avoiding the local water supply and certain foods are critical.</p>
        <p>
<bold>Endemic countries</bold>
</p>
        <p>Collaboration between physicians, nurses, pharmacists, public and community health workers, and civil society partners&#x000a0;is essential to implement typhoid vaccine programs effectively. Accurate assessments of typhoid epidemiology and other critical health issues, funding and secure vaccine supply, community trust building, safe transport, storage and administration of vaccines, and follow-up for adverse events&#x000a0;are necessary&#x000a0;for&#x000a0;optimal program implementation. All TCVs require&#x000a0;strict&#x000a0;cold chain maintenance.</p>
        <p>The WHO gives the highest priority for TCV use to highly endemic countries and those with high rates of XDR typhoid.<xref ref-type="bibr" rid="article-30720.r4">[4]</xref>&#x000a0;TCVs are preferred&#x000a0;by the&#x000a0;WHO to prevent typhoid fever due to their immunological properties,&#x000a0;efficacy in young children, and prolonged duration of immunity&#x000a0;compared to&#x000a0;unconjugated vaccines.<xref ref-type="bibr" rid="article-30720.r4">[4]</xref>&#x000a0;Previously, only&#x000a0;Typbar-TCV<sup>&#x000ae;</sup>&#x000a0;was WHO-prequalified, raising supply concerns. Since then, Vi-CMR<sub>197</sub><sup>TM</sup> and SKYTyphoid<sup>TM&#x000a0;</sup>have become prequalified. A&#x000a0;stable and cost-effective vaccine supply requires multiple&#x000a0;vaccine types and manufacturers; several newer vaccines are at various stages of development.<xref ref-type="bibr" rid="article-30720.r14">[14]</xref>&#x000a0;The Vi-rEPA vaccine is not currently commercially available.</p>
        <p>As of June 2024, 6 countries have incorporated TCV into their routine immunization schedules in combination with WASH interventions.<xref ref-type="bibr" rid="article-30720.r23">[23]</xref>&#x000a0;Several other countries are currently in the application or implementation process. Distribution is&#x000a0;handled by international agencies such as the internationally-funded Gavi Global Vaccine Alliance.<xref ref-type="bibr" rid="article-30720.r23">[23]</xref>&#x000a0;In addition to <italic toggle="yes">S</italic> Typhi vaccination, effective prevention of enteric fever requires a separate vaccine to prevent&#x000a0;<italic toggle="yes">S</italic> Paratyphi. While the Ty21 vaccine&#x000a0;demonstrates some cross-reactivity for Salmonella Paratyphi B, it does not confer sufficient immunity to be used clinically for S Paratyphi B prevention and is not FDA-approved for this purpose.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/typhoid-and-paratyphoid-fever#prevent">[25]</ext-link>&#x000a0;Improved diagnostic tools, water, sanitation, and hygiene infrastructure are essential to eliminate&#x000a0;enteric fever as a global health threat.&#x000a0;</p>
        <p>
<bold>Other Prevention Measures&#x000a0;</bold>
</p>
        <p>Preventing typhoid fever and other enteric illnesses requires safe food and water practices and infrastructure. For travelers and people living in risk areas, washing hands before eating, eating foods thoroughly cooked and served hot, and eating personally peeled fruits are essential safeguards. Drinking water should be boiled, chemically disinfected,&#x000a0;or bottled and personally opened. Adequate water, sanitation, and hygiene (WASH) infrastructure is vital to decrease the incidence of typhoid fever in endemic countries. Developing an <italic toggle="yes">S</italic> Paratyphi vaccine&#x000a0;is critical in the global fight against enteric fever and antimicrobial resistance, particularly in countries where S Paratyphi comprises a large part of the enteric fever burden.</p>
      </sec>
      <sec id="article-30720.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30720&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30720">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30720/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30720">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-30720.s11">
        <title>References</title>
        <ref id="article-30720.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Batool</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Qamar</surname>
                <given-names>ZH</given-names>
              </name>
              <name>
                <surname>Salam</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Yousafzai</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Ashorn</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Qamar</surname>
                <given-names>FN</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of typhoid vaccines against culture-confirmed Salmonella Typhi in typhoid endemic countries: a systematic review and meta-analysis.</article-title>
            <source>Lancet Glob Health</source>
            <year>2024</year>
            <month>Apr</month>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>e589</fpage>
            <page-range>e589-e598</page-range>
            <pub-id pub-id-type="pmid">38485426</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30720.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <collab>GRAM Typhoid Collaborators</collab>
            <article-title>Estimating the subnational prevalence of antimicrobial resistant Salmonella enterica serovars Typhi and Paratyphi A infections in 75 endemic countries, 1990-2019: a modelling study.</article-title>
            <source>Lancet Glob Health</source>
            <year>2024</year>
            <month>Mar</month>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>e406</fpage>
            <page-range>e406-e418</page-range>
            <pub-id pub-id-type="pmid">38365414</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30720.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jackson</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Iqbal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mahon</surname>
                <given-names>B</given-names>
              </name>
              <collab>Centers for Disease Control and Prevention (CDC)</collab>
            </person-group>
            <article-title>Updated recommendations for the use of typhoid vaccine--Advisory Committee on Immunization Practices, United States, 2015.</article-title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <year>2015</year>
            <month>Mar</month>
            <day>27</day>
            <volume>64</volume>
            <issue>11</issue>
            <fpage>305</fpage>
            <page-range>305-8</page-range>
            <pub-id pub-id-type="pmid">25811680</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30720.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>World Health Organization</surname>
              </name>
            </person-group>
            <article-title>Typhoid vaccines: WHO position paper, March 2018 - Recommendations.</article-title>
            <source>Vaccine</source>
            <year>2019</year>
            <month>Jan</month>
            <day>07</day>
            <volume>37</volume>
            <issue>2</issue>
            <fpage>214</fpage>
            <page-range>214-216</page-range>
            <pub-id pub-id-type="pmid">29661581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30720.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Britto</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Dougan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pollard</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>A systematic review of antimicrobial resistance in Salmonella enterica serovar Typhi, the etiological agent of typhoid.</article-title>
            <source>PLoS Negl Trop Dis</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>12</volume>
            <issue>10</issue>
            <fpage>e0006779</fpage>
            <pub-id pub-id-type="pmid">30307935</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30720.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumar Rai</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Saluja</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chaudhary</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tamrakar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kanodia</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Giri</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Shrestha</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Uranw</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>IY</given-names>
              </name>
              <name>
                <surname>Kyung</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Vemula</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reddy E</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Jo</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Ryu</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Mojares</surname>
                <given-names>ZR</given-names>
              </name>
              <name>
                <surname>Wartel</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Sahastrabuddhe</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.</article-title>
            <source>Lancet Infect Dis</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>529</fpage>
            <page-range>529-540</page-range>
            <pub-id pub-id-type="pmid">34942090</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30720.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amicizia</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Arata</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zangrillo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Panatto</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gasparini</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Overview of the impact of Typhoid and Paratyphoid fever. Utility of Ty21a vaccine (Vivotif&#x000ae;).</article-title>
            <source>J Prev Med Hyg</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>58</volume>
            <issue>1</issue>
            <fpage>E1</fpage>
            <page-range>E1-E8</page-range>
            <pub-id pub-id-type="pmid">28515625</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30720.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rappuoli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>De Gregorio</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Costantino</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>On the mechanisms of conjugate vaccines.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2019</year>
            <month>Jan</month>
            <day>02</day>
            <volume>116</volume>
            <issue>1</issue>
            <fpage>14</fpage>
            <page-range>14-16</page-range>
            <pub-id pub-id-type="pmid">30578318</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30720.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Meiring</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Chasweka</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Misiri</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mwakiseghile</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wachepa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Banda</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Shumba</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kawalazira</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dube</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Nampota-Nkomba</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Nyirenda</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Girmay</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Datta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jamka</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Tracy</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Laurens</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Heyderman</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Neuzil</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>MA</given-names>
              </name>
              <collab>TyVAC team</collab>
            </person-group>
            <article-title>Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children.</article-title>
            <source>Lancet</source>
            <year>2024</year>
            <month>Feb</month>
            <day>03</day>
            <volume>403</volume>
            <issue>10425</issue>
            <fpage>459</fpage>
            <page-range>459-468</page-range>
            <pub-id pub-id-type="pmid">38281499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30720.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mohamed Taha</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abouelmagd</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mahmoud</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Elkasaby</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bonilla-Aldana</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Luna</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rodriguez-Morales</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Safety and immunogenicity of Vi-diphtheria toxoid typhoid conjugate vaccine among children below 2&#x02009;years: a systematic review and meta-analysis.</article-title>
            <source>Front Microbiol</source>
            <year>2024</year>
            <volume>15</volume>
            <fpage>1385834</fpage>
            <pub-id pub-id-type="pmid">38646637</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30720.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yousafzai</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Karim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Qureshi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kazi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Memon</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Junejo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khawaja</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Ur Rehman</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ansari</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Ali</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ujjan</surname>
                <given-names>IU</given-names>
              </name>
              <name>
                <surname>Lohana</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Memon</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Hussain</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nigar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bar-Zeev</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Qamar</surname>
                <given-names>FN</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness of typhoid conjugate vaccine against culture-confirmed Salmonella enterica serotype Typhi in an extensively drug-resistant outbreak setting of Hyderabad, Pakistan: a cohort study.</article-title>
            <source>Lancet Glob Health</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>9</volume>
            <issue>8</issue>
            <fpage>e1154</fpage>
            <page-range>e1154-e1162</page-range>
            <pub-id pub-id-type="pmid">34297962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30720.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Milligan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Neuberger</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Vaccines for preventing typhoid fever.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2018</year>
            <month>May</month>
            <day>31</day>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>CD001261</fpage>
            <pub-id pub-id-type="pmid">29851031</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30720.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thuluva</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Paradkar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Matur</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Turaga</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gv</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>A multicenter, single-blind, randomized, phase-2/3 study to evaluate immunogenicity and safety of a single intramuscular dose of biological E's Vi-capsular polysaccharide-CRM<sub>197</sub> conjugate typhoid vaccine (TyphiBEV<sup>TM</sup>) in healthy infants, children, and adults in comparison with a licensed comparator.</article-title>
            <source>Hum Vaccin Immunother</source>
            <year>2022</year>
            <month>Nov</month>
            <day>30</day>
            <volume>18</volume>
            <issue>5</issue>
            <fpage>2043103</fpage>
            <pub-id pub-id-type="pmid">35333702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30720.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nampota-Nkomba</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Jamka</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Fecteau</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Neuzil</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Using Typhoid Conjugate Vaccines to Prevent Disease, Promote Health Equity, and Counter Drug-Resistant Typhoid Fever.</article-title>
            <source>Open Forum Infect Dis</source>
            <year>2023</year>
            <month>May</month>
            <volume>10</volume>
            <issue>Suppl 1</issue>
            <fpage>S6</fpage>
            <page-range>S6-S12</page-range>
            <pub-id pub-id-type="pmid">37274532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30720.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tamrakar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Poudel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Thapa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khadgi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thapa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tamrakar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shrestha</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Madhup</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rai</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Saluja</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sahastrabuddhe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shrestha</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Safety and immunogenicity of conjugate vaccine for typhoid (Vi-DT): Finding from an observer-blind, active-controlled, randomized, non-inferiority, phase III clinical trial among healthy volunteers.</article-title>
            <source>Hum Vaccin Immunother</source>
            <year>2024</year>
            <month>Dec</month>
            <day>31</day>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>2301631</fpage>
            <pub-id pub-id-type="pmid">38189360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30720.r16">
          <label>16</label>
          <element-citation publication-type="book">
            <chapter-title>Typhoid Vaccine</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2020</year>
            <month>7</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">30000191</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30720.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meiring</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Khanam</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Basnyat</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Charles</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Crump</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Debellut</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Holt</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Kariuki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mugisha</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Neuzil</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Parry</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Pitzer</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Pollard</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Qadri</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Typhoid fever.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2023</year>
            <month>Dec</month>
            <day>14</day>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>71</fpage>
            <pub-id pub-id-type="pmid">38097589</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30720.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marchello</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Birkhold</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Crump</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Complications and mortality of typhoid fever: A global systematic review and meta-analysis.</article-title>
            <source>J Infect</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>81</volume>
            <issue>6</issue>
            <fpage>902</fpage>
            <page-range>902-910</page-range>
            <pub-id pub-id-type="pmid">33144193</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30720.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parry</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Qamar</surname>
                <given-names>FN</given-names>
              </name>
              <name>
                <surname>Rijal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McCann</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Basnyat</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>What Should We Be Recommending for the Treatment of Enteric Fever?</article-title>
            <source>Open Forum Infect Dis</source>
            <year>2023</year>
            <month>May</month>
            <volume>10</volume>
            <issue>Suppl 1</issue>
            <fpage>S26</fpage>
            <page-range>S26-S31</page-range>
            <pub-id pub-id-type="pmid">37274536</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30720.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Booth</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Patil</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Barnes</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Greenwald</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Sztein</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Effect of the live oral attenuated typhoid vaccine, Ty21a, on systemic and terminal ileum mucosal CD4+ T memory responses in humans.</article-title>
            <source>Int Immunol</source>
            <year>2019</year>
            <month>Feb</month>
            <day>15</day>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>101</fpage>
            <page-range>101-116</page-range>
            <pub-id pub-id-type="pmid">30346608</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30720.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Masuet-Aumatell</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Atouguia</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Typhoid fever infection - Antibiotic resistance and vaccination strategies: A narrative review.</article-title>
            <source>Travel Med Infect Dis</source>
            <year>2021</year>
            <season>Mar-Apr</season>
            <volume>40</volume>
            <fpage>101946</fpage>
            <pub-id pub-id-type="pmid">33301931</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30720.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hughes</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Birhane</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Dorough</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Caidi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tagg</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Snyder</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Altman</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Boyle</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Robbins</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Waechter</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Cody</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mintz</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Gutelius</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Langley</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Francois Watkins</surname>
                <given-names>LK</given-names>
              </name>
            </person-group>
            <article-title>Extensively Drug-Resistant Typhoid Fever in the United States.</article-title>
            <source>Open Forum Infect Dis</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>8</volume>
            <issue>12</issue>
            <fpage>ofab572</fpage>
            <pub-id pub-id-type="pmid">34917695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30720.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shakya</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pollard</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Typhoid conjugate vaccines: a step towards typhoid control.</article-title>
            <source>Lancet Glob Health</source>
            <year>2024</year>
            <month>Apr</month>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>e535</fpage>
            <page-range>e535-e536</page-range>
            <pub-id pub-id-type="pmid">38485415</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
